Drugs / BRC-002
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07699120 | Jun → Oct 2026 expected | — | Biopharmaceutical Research Company | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06393101 | Jun 2024 → Jun 2029 expected | complex regional pain syndrome | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07224932 | Dec 2025 → Jan 2026 overdue | restless legs syndrome | University of Colorado, Denver | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRC-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07224932 ↗ |
| Route | Oral | “receive oral investigational product” NCT07224932 ↗ |